Stryker Corporation (SYK)
Stryker Corporation (SYK) Q3 2024 Earnings Call Transcript
Stryker Corporation. (NYSE:SYK ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Lawrence Biegelsen - Wells Fargo Securities Joanne Wuensch - Citi Ryan Zimmerman - BTIG Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Companies Vijay Kumar - Evercore ISI Matthew Miksic - Barclays Steven Litchman - Oppenheimer & Co David Roman - Goldman Sachs Christopher Pasquale - Nephron Research Jason Wittes - Roth MKM Michael Matson - Needham & Company Danielle Antalffy - UBS Equities Richard Newitter - Truist Securities Matthew Taylor - Jefferies Jeffrey Johnson - Robert W.
Here's What Key Metrics Tell Us About Stryker (SYK) Q3 Earnings
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stryker (SYK) Surpasses Q3 Earnings and Revenue Estimates
Stryker (SYK) came out with quarterly earnings of $2.87 per share, beating the Zacks Consensus Estimate of $2.78 per share. This compares to earnings of $2.46 per share a year ago.
Strong Segmental Performance to Drive Stryker's Q3 Earnings
SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Insights Into Stryker (SYK) Q3: Wall Street Projections for Key Metrics
Evaluate the expected performance of Stryker (SYK) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Stryker: A High Quality MedTech Name Investors Should Own
Stryker Corporation is a global leader in medical devices, with strong growth prospects driven by an aging population and technological advancements. SYK has a robust track record of double-digit earnings growth and high single-digit organic revenue growth, outperforming peers. Stryker's innovative products, like the Mako robot, and strategic acquisitions bolster its market position and future growth potential.
Stryker: More Earnings Growth And Higher Prices Ahead
Stryker Corporation stock is recommended as a Buy due to its steady earnings growth, margin improvements, and strategic acquisitions, with a one-year price target 12.66% higher. Recent financial results show robust performance, with net sales up 8.5%, adjusted EPS up 10.6%, and a healthy balance sheet with reduced long-term debt. Stryker's growth prospects are supported by organic growth, acquisitions, and expanding margins, alongside a modest but growing dividend, making it an attractive stock for growth investors.
Stryker's Acquisition Spree: Double-Digit Growth on the Horizon
Stryker SYK is a medical device company that has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry. The company has often acquired other firms to boost its competitiveness and add capabilities.
Stryker's Acquisition Spree: Double-Digit Growth on the Horizon
Stryker NYSE: SYK is a medical device company that has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry. The company has often acquired other firms to boost its competitiveness and add capabilities.
Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?
Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
SYK Stock May Gain From Completion of Vertos Medical Acquisition
Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.
Reasons to Retain Stryker Stock in Your Portfolio for Now
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
